A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 03 May 2018
At a glance
- Drugs BMS 986205 (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 26 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to change in business objectives
- 15 Mar 2018 Planned End Date changed from 23 May 2025 to 20 Aug 2025.
- 15 Mar 2018 Planned primary completion date changed from 26 Jan 2021 to 25 Apr 2021.